Skip to main content
. 2025 Apr 11;263(7):1899–1905. doi: 10.1007/s00417-025-06821-w

Table 2.

Clinical characteristics of patients with follow-up

Age Gender Eye BCVAb (logMAR) Concomitant eye disease Extent of RRD* Macula off/on PVR Procedure Complication Follow up time (months) Final outcome BCVAf (logMAR)
1 95 m OS 2.3 glaucoma 1 off no SB, PPV, C2F6, laserpexy no 1.6 RA 0.7
2 96 f OD 0.5 amd 1 on no PPV,silicone oil, laserpexy decalin leakage 6 RA 0.7
3 94 m OS 2.3 no 2 off yes PPV, silicone oil, laserpexy after 3 months silicon emulsification 3 RA 0.3
4 91 f OS 2.7 high myopia 4 off yes PPV, C2F6 no 1 RD 2.3
5 93 m OS 1.9 no 2 off no

SB,

2nd procedure:

PPV, silicone oil, laserpexy

no 9 RA 0.5
6 95 m OD 2.3 no n.d on no PPV, C2F6, cryopexy no 3 RA 0.4
7 93 f OD 2.3 glaucoma 4 off no PPV, silicone oil, laserpexy no 1 RD 2.3
8 95 m OS 2.3 hemianopia 4 off yes SB, PPV, silicone oil no 3 RA 2.3
9 93 f OS 2.7 no 2 off no

PPV, C2F6, laserpexy

2nd procedure:

PPV, silicone oil, laserpexy

subchoroidal hemorrhage 37.6 RD 1.9
10 93 f OS 2.7 no 4 off no PPV, silicone oil, laserpexy no 2 RD 1.3

m male, f female, OD right eye, OS left eye, BCVAb baseline best corrected visual acuity, n.d. not detected, AMD Age related macular degeneration, PVR proliferative vitreoretinopathy, PPV pars plana vitrectomy, SB scleral buckling, RA reattachment, PD persistent detachment, RD redetachment, BCVA f final best corrected visual acuity

*The extent of RRD in involved quadrants